A Phase 3 interventional study of NewGam in Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy, sponsored by Octapharma. Completed at 26 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Octapharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy
Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy ("ProCID trial")
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical evidence of peripheral neuropathy from another cause such as
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
Drug: NewGam
All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
Drug: NewGam
All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
Drug: NewGam
In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
Also known as: Panzyga
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Efficacy - Proportion of responders in the 1.0 g/kg NewGam arm at Week 24 (Termination Visit) relative to baseline (Week 0). A responder being defined as a patient with a decrease of at least 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (a scale from 0 to 10, from healthy to unable to make any purposeful movements with arms and/or legs)
Time frame: at Week 24
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline compared to the 1.0 g/kg arm, based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score
Time frame: at Week 24
Grip Strength Score
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the grip strength (Martin Vigorimeter) using the previously published minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa)
Time frame: at Week 24
Inflammatory Rasch-built Overall Disability Scale (I-RODS Score)
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated
Time frame: at Week 24
Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale by at least 1 point from the value at baseline (Week 0)
Time frame: Week 24
Mean Change in Grip Strength
Mean change from baseline (Week 0) to Termination Visit in grip strength of both hands (assessed by Martin vigorimeter). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.
Time frame: Up to 24 weeks
Inflammatory Rasch-built Overall Disability Scale (I-RODS)
Mean change from baseline (Week 0) to Termination Visit in Inflammatory Rasch-built overall disability sum score (I-RODS using the concept of MCID-SE as recently reported) and number of improvers. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.
Time frame: Up to 24 weeks
Motor Nerves
Mean change from baseline (Week 0) to Termination Visit in sum of the distal evoked amplitude of 4 right sided and 4 left sided motor nerves (peroneal, tibial, ulnar and median). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.
Time frame: Up to 24 weeks
Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)
Mean change from baseline (Week 0) to Termination Visit in Pain Intensity Numeric Rating Scale (PI-NRS). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. The Pain Intensity Numeric Rating Scale (PI-NRS, a numeric scale where 0 = no pain and 10 = worst possible pain) is an 11-point scale for patient self-reporting of pain. A higher value represents a worse outcome.
Time frame: Up to 24 weeks
Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)
Time to first confirmed worsening on the I-RODS scale. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome. Worsening is determined using the concept of MCID (minimum clinically important difference) using the individually obtained standard errors (MCID-SE).
Time frame: 24 weeks
1 Point Decrease in the INCAT Disability Score
Time to 1 point decrease (improvement of disability) in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score
Time frame: 24 weeks
Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)
Time to decrease in Inflammatory Rasch-built overall disability scale (I-RODS) scores
Time frame: 24 weeks
| Milestone | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Started | 35 | 69 | 38 |
| Completed | 28 | 61 | 34 |
| Not completed | 7 | 8 | 4 |
Efficacy - Proportion of responders in the 1.0 g/kg NewGam arm at Week 24 (Termination Visit) relative to baseline (Week 0). A responder being defined as a patient with a decrease of at least 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (a scale from 0 to 10, from healthy to unable to make any purposeful movements with arms and/or legs)
| proportion of subjects | 1.0 g/kg NewGam |
|---|---|
| Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score | .7971 |
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline compared to the 1.0 g/kg arm, based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score
| Proportion of responders | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score | .6471 | .7971 | .9167 |
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the grip strength (Martin Vigorimeter) using the previously published minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa)
| Proportion of responders | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Grip Strength Score | .5588 | .6522 | .8333 |
Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated
| Proportion of responders | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Inflammatory Rasch-built Overall Disability Scale (I-RODS Score) | .3824 | .5507 | .7222 |
Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale by at least 1 point from the value at baseline (Week 0)
| days | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Mean change from baseline (Week 0) to Termination Visit in grip strength of both hands (assessed by Martin vigorimeter). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.
| kPa | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Dominant Hand | 23.91 ± 25.290 | 19.38 ± 20.377 | 26.06 ± 25.030 |
| Non-dominant Hand | 23.94 ± 24.600 | 17.43 ± 19.916 | 24.53 ± 22.247 |
Mean change from baseline (Week 0) to Termination Visit in Inflammatory Rasch-built overall disability sum score (I-RODS using the concept of MCID-SE as recently reported) and number of improvers. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.
| score on a scale | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Inflammatory Rasch-built Overall Disability Scale (I-RODS) | 11.38 ± 12.485 | 10.32 ± 10.836 | 13.86 ± 11.981 |
Mean change from baseline (Week 0) to Termination Visit in sum of the distal evoked amplitude of 4 right sided and 4 left sided motor nerves (peroneal, tibial, ulnar and median). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.
| mV | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Motor Nerves | 2.16 ± 6.332 | 2.69 ± 6.688 | 3.93 ± 9.298 |
Mean change from baseline (Week 0) to Termination Visit in Pain Intensity Numeric Rating Scale (PI-NRS). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. The Pain Intensity Numeric Rating Scale (PI-NRS, a numeric scale where 0 = no pain and 10 = worst possible pain) is an 11-point scale for patient self-reporting of pain. A higher value represents a worse outcome.
| score on a scale | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale) | -2.29 ± 3.040 | -2.19 ± 2.907 | -2.17 ± 3.256 |
Time to first confirmed worsening on the I-RODS scale. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome. Worsening is determined using the concept of MCID (minimum clinically important difference) using the individually obtained standard errors (MCID-SE).
| days | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to 1 point decrease (improvement of disability) in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score
| days | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| 1 Point Decrease in the INCAT Disability Score | 22.0 (22.0 to 24.0) | 26.0 (22.0 to 43.0) | 23.0 (22.0 to 43.0) |
Time to decrease in Inflammatory Rasch-built overall disability scale (I-RODS) scores
| days | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam |
|---|---|---|---|
| Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Up to 36 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NGAM 0.5 g/kg | 0/35 (0%) | 1/35 (2.9%) | 20/35 (57.1%) |
| NGAM 1.0 g/kg | 1/69 (1.4%) | 4/69 (5.8%) | 45/69 (65.2%) |
| NGAM 2.0 g/kg | 1/38 (2.6%) | 1/38 (2.6%) | 24/38 (63.2%) |
| Total | 2/142 (1.4%) | 6/142 (4.2%) | 88/142 (62%) |
| Event | NGAM 0.5 g/kg | NGAM 1.0 g/kg | NGAM 2.0 g/kg | Total |
|---|---|---|---|---|
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/35 | 0/69 | 0/38 | 1/142 |
| EncephalitisInfections and infestations | 0/35 | 0/69 | 1/38 | 1/142 |
| OsteomyelitisInfections and infestations | 0/35 | 1/69 | 0/38 | 1/142 |
| PneumoniaInfections and infestations | 0/35 | 1/69 | 0/38 | 1/142 |
| Cardio-respiratory ArrestCardiac disorders | 0/35 | 1/69 | 0/38 | 1/142 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/35 | 1/69 | 0/38 | 1/142 |
| Deafness unilateralEar and labyrinth disorders | 0/35 | 1/69 | 0/38 | 1/142 |
| HeadacheNervous system disorders | 0/35 | 1/69 | 0/38 | 1/142 |
| VomitingGastrointestinal disorders | 0/35 | 1/69 | 0/38 | 1/142 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 1/69 | 0/38 | 1/142 |
| Event | NGAM 0.5 g/kg | NGAM 1.0 g/kg | NGAM 2.0 g/kg | Total |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/35 | 9/69 | 8/38 | 19/142 |
| Dermatitis allergicSkin and subcutaneous tissue disorders | 4/35 | 5/69 | 4/38 | 13/142 |
| PyrexiaGeneral disorders | 3/35 | 6/69 | 2/38 | 11/142 |
| Blood pressure increasedInvestigations | 3/35 | 6/69 | 0/38 | 9/142 |
| ChillsGeneral disorders | 3/35 | 3/69 | 1/38 | 7/142 |
| UrticariaSkin and subcutaneous tissue disorders | 3/35 | 0/69 | 0/38 | 3/142 |
| Body temperature increasedInvestigations | 2/35 | 4/69 | 3/38 | 9/142 |
| NauseaGastrointestinal disorders | 1/35 | 1/69 | 3/38 | 5/142 |
| Blood lactate dehydrogenase increasedInvestigations | 0/35 | 5/69 | 0/38 | 5/142 |
| LeukopeniaBlood and lymphatic system disorders | 1/35 | 5/69 | 0/38 | 6/142 |
| Age, Continuous(years) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| Mean | 52.49 ± 14.449 | 56.32 ± 14.616 | 58.05 ± 13.764 | 55.84 ± 14.398 |
| Sex: Female, Male(Participants) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| Female | 13 | 31 | 14 | 58 |
| Male | 22 | 38 | 24 | 84 |
| Race (NIH/OMB)(Participants) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 35 | 69 | 38 | 142 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kg) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| Mean | 84.09 ± 16.511 | 81.74 ± 16.333 | 77.68 ± 75.50 | 81.23 ± 79.00 |
| Height(cm) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| Mean | 173.46 ± 9.506 | 172.81 ± 8.304 | 171.61 ± 9.030 | 172.65 ± 8.770 |
| BMI(kg/m^2) | 0.5 g/kg NewGam | 1.0 g/kg NewGam | 2.0 g/kg NewGam | Total |
|---|---|---|---|---|
| Mean | 27.92 ± 4.873 | 27.27 ± 4.588 | 26.33 ± 5.231 | 27.18 ± 4.837 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Sep 2019, 23 months.
Results were first posted in Feb 2021, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous